In:
Frontiers in Endocrinology, Frontiers Media SA, Vol. 14 ( 2023-5-24)
Abstract:
Changes in N-glycosylation have been described in numerous diseases and are being considered as biomarkers of ongoing pathological condition. Previous studies demonstrated the interrelation of N-glycosylation and type 1 diabetes (T1D), particularly linking serum N-glycan changes with complications accompanying the disease. Moreover, the role of complement component C3 in diabetic nephropathy and retinopathy has been implicated, and C3 N-glycome was found to be altered in young T1D patients. Therefore, we investigated associations between C3 N-glycan profiles and albuminuria and retinopathy accompanying T1D, as well as glycosylation connection with other known T1D complication risk factors. Research design and methods Complement component C3 N-glycosylation profiles have been analyzed from 189 serum samples of T1D patients (median age 46) recruited at a Croatian hospital centre. Using our recently developed high-throughput method, relative abundances of all six of the C3 glycopeptides have been determined. Assessment of C3 N-glycome interconnection with T1D complications, hypertension, smoking status, estimated glomerular filtration rate (eGFR), glycaemic control and duration of the disease was done using linear modelling. Results Significant changes of C3 N-glycome in severe albuminuria accompanying type 1 diabetes were observed, as well as in T1D subjects with hypertension. All except one of the C3 glycopeptides proved to be associated with measured HbA1c levels. One of the glycoforms was shown to be changed in non-proliferative T1D retinopathy. Smoking and eGFR showed no effect on C3 N-glycome. Furthermore, C3 N-glycosylation profile was shown to be independent of disease duration. Conclusion This study empowered the role of C3 N-glycosylation in T1D, showing value in distinguishing subjects with different diabetic complications. Being independent of the disease duration, these changes may be associated with the disease onset, making C3 N-glycome a potential novel marker of the disease progression and severity.
Type of Medium:
Online Resource
ISSN:
1664-2392
DOI:
10.3389/fendo.2023.1101154
DOI:
10.3389/fendo.2023.1101154.s001
DOI:
10.3389/fendo.2023.1101154.s002
DOI:
10.3389/fendo.2023.1101154.s003
DOI:
10.3389/fendo.2023.1101154.s004
DOI:
10.3389/fendo.2023.1101154.s005
DOI:
10.3389/fendo.2023.1101154.s006
DOI:
10.3389/fendo.2023.1101154.s007
DOI:
10.3389/fendo.2023.1101154.s008
DOI:
10.3389/fendo.2023.1101154.s009
DOI:
10.3389/fendo.2023.1101154.s010
DOI:
10.3389/fendo.2023.1101154.s011
DOI:
10.3389/fendo.2023.1101154.s012
DOI:
10.3389/fendo.2023.1101154.s013
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2023
detail.hit.zdb_id:
2592084-4